EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes Trial

Sahar Naderi, Danielle Brennan, Na Li, A Michael Lincoff, Stephen J Nicholls, Steven E Nissen, Jorge Plutzky, Heather A Powell, Paula Robinson, Leslie Cho iD

Clinical Cardiology · 2026

DOI: 10.1002/clc.70288 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Cardiology, 2026. Verfasst von Sahar Naderi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Kaiser Permanente Northern California, Oakland, California, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Cholesterol, LDL, Dicarboxylic Acids, Dyslipidemias. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Esperion Therapeutics, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The CLEAR Outcomes study showed that bempedoic acid reduced LDL cholesterol (LDL‐C) and cardiovascular risk in patients with statin intolerance. CLEAR Outcomes included 48% female participants.

Objective

To describe the differences in baseline clinical characteristics and tolerability of bempedoic acid by sex.

Methods

Descriptive analysis of data from a double‐blind, randomized, placebo‐controlled cardiovascular outcome study in which 13 970 primary or secondary prevention patients at high cardiovascular risk with statin intolerance and baseline LDL‐C ≥ 100 mg/dL were randomized to bempedoic acid 180 mg daily or placebo.

Results

At baseline, females (48%) were older, with less use of lipid lowering therapies, and more often without an ASCVD history. Females had more peripheral and cerebrovascular disease and less coronary artery disease. The incidence of myalgia was 5.4% versus 5.9% for females and 5.8% vs 7.6% for males treated with bempedoic acid versus placebo, respectively. Treatment discontinuation rates were lower with bempedoic acid than placebo in females (30.5% vs 33.4%) and males (27.9% vs 30.0%). Bempedoic acid discontinuation because of myalgia was comparable between females (1.8% vs. 1.6%) and males (1.7% vs 2.1%) versus placebo, respectively.

Conclusions

This is the only cardiovascular outcomes trial to date that exclusively enrolled patients with statin intolerance, and the largest contemporary study of lipid lowering therapy in females, a group historically underrepresented in clinical trials. Bempedoic acid was equally tolerated by both sexes and represents a viable alternative to statins to reduce cardiovascular risk. Trial Registration ClinicalTrials.gov identifier: NCT02993406.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesCholesterol, LDLDicarboxylic AcidsDyslipidemiasFatty AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsPrimary PreventionSecondary PreventionAgedFemaleHumansMaleMiddle AgedBiomarkersDouble-Blind MethodIncidenceSex FactorsTreatment Outcome

Stichwörter der Autor:innen

adverse eventsbempedoic acidlow‐density lipoprotein cholesterolsexstatin intolerancetolerability

Substanzen

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidBiomarkersCholesterol, LDLDicarboxylic AcidsFatty AcidsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Division of Cardiology, Kaiser Permanente Northern California, Oakland, California, USA.
  • Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, Ohio, USA.
  • Esperion Therapeutics Inc., Ann Arbor, Michigan, USA.
  • Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia.
  • Cleveland Clinic, Cleveland, Ohio, USA.
  • Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Leslie Cho

Förderung

  • Esperion Therapeutics, Inc.

Zitieren

APA

Naderi, S., Brennan, D., Li, N., Lincoff, A. M., Nicholls, S. J., Nissen, S. E., Plutzky, J., Powell, H. A., Robinson, P., & Cho, L. (2026). Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes Trial. Clinical Cardiology. https://doi.org/10.1002/clc.70288

Vancouver

Naderi S, Brennan D, Li N, Lincoff AM, Nicholls SJ, Nissen SE, et al. Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes Trial. Clinical Cardiology. 2026. doi:10.1002/clc.70288

BibTeX
@article{Naderi2026,
  author = {Naderi, Sahar and Brennan, Danielle and Li, Na and Lincoff, A Michael and Nicholls, Stephen J and Nissen, Steven E and Plutzky, Jorge and Powell, Heather A and Robinson, Paula and Cho, Leslie},
  title = {Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes Trial},
  journal = {Clinical Cardiology},
  year = {2026},
  doi = {10.1002/clc.70288}
}
Kostenlos starten →